Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner by Barrick, Cordelia J. et al.
Loss of receptor activity-modifying protein 3 exacerbates
cardiac hypertrophy and transition to heart failure in a sex-
dependent manner
Cordelia J. Barricka, Patricia M. Lenharta, Ryan T. Dackora, Elizabeth Naglea, and Kathleen
M. Carona,*
aDepartment of Cell & Molecular Physiology, The University of North Carolina, Chapel Hill, North
Carolina, USA 27599
Abstract
Sex differences exist in the hypertrophic response, cardiac remodeling, and transition to heart
failure of hypertensive patients, and while some of these differences are likely influenced by
estrogen, the genetic pathways downstream of estrogen that impact on cardioprotection have yet to
be fully elucidated. We have previously shown that the cardioprotective effects of adrenomedullin
(AM), an emerging clinical biomarker for cardiovascular disease severity, vary with sex in mouse
models. AM signaling during cardiovascular stress is strongly modulated by receptor activity-
modifying protein 3 (RAMP3) via its interaction with the G protein-coupled receptor calcitonin
receptor-like receptor (CLR). Like AM, RAMP3 expression is potently regulated by estrogen, and
so we sought to determine the consequences of genetic Ramp3 loss on cardiac adaptation to
chronic hypertension, with a particular focus on characterizing potential sex differences. We
generated and bred RAMP3−/− mice to RenTgMK mice that consistently display severe
angiotensin II-mediated CV disease and compared CV disease progression in RenTgMK to that of
RenTgMK:RAMP3−/− offspring. As expected, RAMP3 gene expression was higher in
cardiovascular tissues of RenTgMK mice and more strongly up-regulated in female RenTgMK
mice relative to wildtype controls. RAMP3 loss did not affect the development of hypertension or
the presence and severity of perivascular and interstitial fibrosis in the left ventricle (LV).
However, echocardiography revealed that while RenTgMK mice developed concentric cardiac
hypertrophy with sustained systolic function, male RenTgMK:RAMP3−/− mice showed evidence
of LV chamber dilatation and depressed systolic function, suggestive of cardiac decompensation.
Consistent with these measures of heart failure, male RenTgMK:RAMP3−/− mice had increased
cardiac apoptosis and elevated activation of Akt. These phenotypes were not present in female
RenTgMK:RAMP3−/− mice. Collectively, these data demonstrate a sex-dependant,
cardioprotective role of RAMP3 in the setting of chronic hypertension.
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1. Introduction
Hypertension is a leading cause of cardiovascular disease morbidity and mortality. Cardiac
hypertrophy, a compensatory response to chronic pressure overload, is seen in most
individuals with chronic hypertension. However, significant sex differences exist in the
hypertrophic response, cardiac remodeling, and transition to heart failure in hypertensive
patients. For example, more rapid induction of hypertrophy occurs in men compared to
women with similar degrees of elevated systolic pressure, while women show preserved
cardiac function and ameliorated pathological remodeling compared to age-matched men
with equivalent hypertension [1]. Premenopausal women have lower incidences of
cardiovascular disease and related mortality than age-matched men, but this protection is
lost with the onset of menopause. Evidence from clinical and experimental studies imply
that a cardioprotective role of estrogen may impart sex differences in cardiac disease
susceptibility [2–6]. However, recent results from the Women’s Health Initiative found no
reduction in CVD risk in postmenopausal women with hormone replacement therapy,
suggesting that estrogen replacement alone is not sufficient to confer protection [7–9].
Therefore, identifying and understanding how genetic factors (particularly those which may
be regulated by estrogen) interact and impact on estrogenic cardioprotection is an area of
intense investigation [10–11].
An important estrogen-regulated cardioprotective factor is adrenomedullin (AM), a 52
amino acid, multifunctional peptide that circulates in the plasma in the low picomolar range.
Numerous clinical studies have recently revealed that increased plasma levels of mid-
regional pro-AM are highly correlated with and effectively predictive of poor clinical
prognoses following myocardial infarction [12–15]. A potent vasodilator, AM is also
directly cardioprotective, enhances cardiac contractility and is given clinically in some
countries to counteract organ damage following myocardial infarction or to treat pulmonary
hypertension [16–22]. While there is a great deal of interest and promise in using AM in the
clinical setting, much remains unknown about how AM and its receptors confer
cardioprotection.
AM receptors consist of an oligomeric complex between the GPCR calcitonin receptor-like
receptor (gene: Calcrl, protein: CLR) and members of the receptor activity modifying
protein (RAMP) family of chaperone proteins [23–24]. Currently, the RAMP family consists
of three proteins (RAMPs 1-3) sharing a similar molecular mass (160 amino acids) and
structure, but differing in sequence homology, tissue distribution, and requirement for
normal embryonic development [25–27]. Any of the RAMPs can pair with CLR in the
endoplasmic reticulum and transport it to the plasma membrane. However, association of
CLR with RAMP2 or RAMP3 constitutes a receptor responsive to AM, while association of
CLR with RAMP1 results in a receptor with affinity for another vasodilator, calcitonin gene
related peptide. Several studies suggest that AM signaling during hypertension and other CV
stress is strongly modulated by the RAMP3/CLR complex [28–30]. Since Ramp3 is robustly
upregulated in the cardiovascular system in other models of hypertension [31–34] and may
mediate CLR turnover [35–36], it has been postulated that RAMP3 is cardioprotective via
altering AM signaling during CV stress. Recently, our laboratory generated RAMP3 null
(Ramp3−/−) mice, which are viable and healthy with normal lifespans [25]. However, the
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physiological consequences of RAMP3 loss in hypertensive disease have not been directly
examined.
A widely used experimental model of chronic hypertension and cardiac hypertrophy is the
RenTgMK mouse. These mice have high and constant secretion of renin from the liver,
elevated circulating levels of angiotensin II, and chronic hypertension [37–39]. Male
RenTgMK have increased cardiac hypertrophy, pathological remodeling, and decreased
survival compared to female RenTgMK mice or wild-type controls. We have previously
shown that these sex differences diverge further with genetic loss of AM [40]. RenTgMK
AM+/− male mice display increased cardiac hypertrophy and fibrosis compared to RenTgMK
male mice with equivalent hypertension, however, these differences are not observed in
female mice. Since, like AM, RAMP3 is potently induced by estrogen and contains
functional estrogen receptor response elements in its promoter [41–42], we hypothesized
that RAMP3 would be cardioprotective in the setting of chronic hypertension, but that this
effect would be modulated by sex. To test this hypothesis, we bred RenTgMK to Ramp3−/−
mice and compared sex-specific phenotypes in RenTgMK and RenTgMK;Ramp3−/−
offspring.
2. Materials and Methods
2.1 Animals
Ramp3 null animals were generated as previously described [25] and crossed to
heterozygous RenTgMK mice . PCR detection of the RenTgMK transgene and the null
Ramp3 allele was performed using previously described primers [37, 39]. With the
exception of longitudinal echocardiographies, all animals used in these studies were between
5–6 months of age and maintained on an isogenic 129S6/SvEv genetic background. Control
animals were wild-type, age- and gender-matched littermates. All experiments were
approved by the Institutional Animal Care and Use Committee of the University of North
Carolina at Chapel Hill.
2.2 Gene Expression Analysis
Ramp3, Acadm/MCAD, and Nppa/ANP gene expression was analyzed by quantitative
reverse transcription (RT)-PCR with the Mx3000P Q-PCR machine from Stratagene. Primer
and probe sequences for detection of Ramp2, Ramp3, Adm and Calcrl gene expression were
previously described [25, 43]. For all other primers and probes, we used a pre-designed,
Assays on Demand primer/probe set (Applied Biosystems). Primer/probe sets for Gapdh
(purchased from Applied Biosystems part #4308313) or for Mouse eukaryotic translation
elongation factor 1 alpha 1 (Primer sequences: 5′-CAGCAAAAATGACCCACCAATG-3′
and 5′-TAAGCTCAGCAAACTTGCATGC-3′, Probe sequence: 5′HEX GCT GGC TTC
ACT GCT CAG GTG ATT ATC C-3′TAMRA) were used as internal controls for all
samples. RNA was isolated from adult tissues with TRIzol reagent (Invitrogen) and
subsequently DNase treated and purified with an RNeasy Mini kit (Qiagen). 1 ug of total
RNA was used to generate cDNA using the High Capacity cDNA Archive kit (Applied
Biosystems). The delta-delta Ct method was used to determine the relative levels of gene
expression and shown as a fold increase over a whole embryo control.
2.3 Measurement of basal blood pressure, heart rate, and urine chemistry
Blood pressures and heart rates were measured on unanesthetized mice by a computerized
tail cuff system [44]. Urinary concentration of sodium and potassium levels were measured
through the UNC-CH Animal Clinical Chemistry Core Facility.
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For determining cardiac chamber to body weight ratios and wet lung weights, mice were
weighed and hearts and lungs were dissected, rinsed in PBS, and weighed. The LV was cut
in half along its axis, fixed in 4% paraformaldehyde and 5μM sections were prepared for
subsequent staining for hemotoxylin and eosin (H&E), Masson’s Trichrome staining, anti-α-
smooth muscle actin (anti-α-SMA), or terminal deoxynucleotidyltransferase-mediated
dUTP-digoxigenin nick end labeling (TUNEL) staining.
2.5 Anti-α-SMA staining
Paraffin sections were deparaffinized, rehydrated, rinsed in distilled H2O and permeabilized
in 4% bovine serum albumin with 0.2% Triton X-100 in PBS. After being washed in PBS,
specimens were incubated with α-smooth muscle actin (α-SMA) (catalogue no. A2547;
Sigma) antibody for 1 h at room temperature. Sections were then washed with PBS and PBS
and incubated with a FITC -labeled donkey anti-mouse secondary antibody and DAPI for
120 min at room temperature. After being washed with PBS, the slides were mounted for
imaging. Images were acquired on a Nikon FXA microscope and processed with Photoshop.
2.6 TUNEL cell death assay
Apoptotic cells were identified in 5-μm paraffin-embedded sections with the ApopTag
Fluorescein In Situ apoptosis detection kit (Chemicon) according to the manufacturer’s
protocol. Images were acquired on a Nikon E800 microscope with a Hammamatsu ORCA-
ER charge-coupled device camera with Metamorph software (Molecular Devices Corp.) and
processed with Photoshop.
2.7 Echocardiography
Transthoracic echocardiography was performed with a 30-MHz probe and the Vevo 660
Ultrasonograph (VisualSonics). Mice were anesthetized with 1–1.5% isoflurane. Heart rate
(HR) was closely monitored and mice were placed under a heat lamp to maintain a constant
body temperature of 37°C. The heart was imaged in a two-dimensional parasternal long-axis
view. An M-mode cursor was positioned perpendicular to the interventricular septum and
the posterior wall of the left ventricle at the level of the papillary muscle. Measurements of
left ventricular (LV) end diameter at diastole (LVED,d), LV end diameter at systole
(LVED,s), LV posterior wall (PW) thickness at diastole (LVPW,d) and LVPW thickness at
systole (LVPW,s) were taken and used to obtain calculated values of percent fractional
shortening (%FS), percent ejection fraction (%EF), cardiac output (CO), and LV mass.
2.8 Western Blotting
Western blots were performed using whole mouse heart lysates. Samples were run on SDS-
PAGE gels and transferred to nitrocellulose membrane. Membranes were blocked for 1 h at
room temperature in 5% BSA in TBST and incubated with rabbit anti-pAKT (Cell Signaling
#4060S) or rabbit anti-pan AKT (Cell Signaling #4691S) primary antibody in 5% BSA in
TBST overnight at 4°C. Membranes were then washed in TBST, incubated with goat anti-
rabbit 680 secondary antibody (Thermo Scientific #35568) for 1 h at room temperature, and
washed in TBST. Blots were imaged using LI-COR. Quantitation was performed with
Image J.
2.9 Statistical analysis
Statistical analysis was performed by one-way analysis of variance followed by Fisher’s
PSLD using JMP software (SAS Institute, Cary, NC), and p < 0.05 was considered
significant. In all figures, error bars represent standard errors of the mean.
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3.1 Gene expression changes in response to loss of Ramp3 or AngII-induced
cardiovascular disease
To determine whether genetic deletion of Ramp3 alters expression of other members of the
adrenomedullin signaling pathway, we analyzed expression of Ramp1, Ramp2, and Calcrl in
heart tissue of male and female Ramp3−/− mice compared to wild type controls. There was
no change in Ramp1 or Ramp2 gene expression in Ramp3−/− mice (Figure 1A,B),
supporting our previous studies which demonstrate independent and non-overlapping
functions of RAMP proteins. Calcrl expression was modestly, yet significantly, increased in
Ramp3−/− hearts, but there were no differences between male and female mice (Figure 1C,
Males: p<0.0002, Females: p<0.05). Therefore, we conclude that genetic loss of Ramp3
does not impact on the expression of other RAMP family members, but causes a modest
compensation in Calcrl gene expression levels in the heart that is not distinguishable
between males and females.
The expression of Ramp3 is consistently upregulated in rodent models of cardiac
hypertrophy, hypertension and heart failure, leading to the hypothesis that increased AM
signaling through RAMP3/CLR may be cardioprotective. However, sex differences in this
response have not been examined. Therefore, we investigated changes in the expression of
Ramp3 in male and female mice heterozygous for the genetically clamped renin transgene,
RenTgMK. In this model of chronic hypertension, Ramp3 gene expression was up-regulated
in cardiovascular tissues (heart, kidney and lung) of RenTgMK mice of both sexes
compared to wild-type littermates, with the greatest Ramp3 induction in the heart (Figure
1D). Since estrogen is known to robustly induce Ramp3 expression [41–42], we expected
and found that female RenTgMK mice had greater increases in Ramp3 gene expression in
all cardiovascular tissues compared to male RenTgMK mice, with a nearly three-fold
increase in cardiac Ramp3 expression.
3.2 Loss of Ramp3 does not affect the development of chronic hypertension in mice over-
expressing renin
A single copy of the RenTgMK transgene elevates plasma renin levels and causes
hypertension, cardiac hypertrophy, cardiovascular end-organ damage, and early death [37].
Consistent with previous reports, the RenTgMK transgene caused an increase in MAP of ≈
40 mmHg in male and female mice compared to wild-type controls (p<0.01; Table 1).
Although the loss of Ramp3 moderately reduced the hypertension induced by the renin
transgene, the RenTgMk;Ramp3−/− animals remained significantly hypertensive compared
to wildtype controls and there was no significant reduction in MAP compared to RenTgMK
animals (Males: RenTgMk;Ramp3−/−=126+/−7 mmHg, Females:
RenTgMK;Ramp3−/−=123+/−5 mmHg; P=0.13 and P=0.25, respectively vs sex matched
RenTgMK mice, Table 1). As previously reported [25], we again found no significant
differences in MAP between Ramp3−/− and wild-type mice (data not shown), and thus data
was pooled. There was also no effect of Ramp3 loss on conscious heart rate (HR) (Table 1).
Therefore, we conclude that genetic deletion of Ramp3 had no effect on the chronic
hypertension that is induced by genetic over-expression of the RenTgMK transgene.
3.3 Loss of RAMP3 exacerbates renal damage in male, but not female, mice with chronic
hypertension
Because RAMP3 is highly expressed in the proximal tubule of the kidney, we were
interested in comparing hypertension-induced renal disease between RenTgMK;Ramp3 −/−
and RenTgMK mice. First, we evaluated the effect of RAMP3 on drinking behavior and
urine production in the RenTgMK mice. Consistent with previous results, RenTgMK mice
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consumed significantly more water (both sexes, p<0.05) and produced more urine (Males: p
<0.01; Females: p<0.05) of dilute osmolality (data not shown) compared to their WT
counterparts (Supplemental Figures 1A and B). Although there were no differences by
RAMP3 genotype in water intake (Males: RenTgMK=5.5 ± 0.4 ml vs
RenTgMK;Ramp3−/−=5.9 ±0.3 ml; Females: RenTgMK= 4.9±0.3 ml vs
RenTgMK;Ramp3−/−=5.7±0.3), urine production (Males: RenTgMK= 2.9 ± 0.4 ml, vs
RenTgMK;Ramp3−/−=2.7±0.5 ml; Females: RenTgMK=2.3±0.4 ml vs
RenTgMK;Ramp3−/−=3.0±0.4 ml) or urine sodium or potassium levels (data not shown),
gender differences emerged with respect to renal pathology. As shown in Figure 2A, the
kidneys of all RenTgMK:Ramp3−/− male mice examined had severe glomerular sclerosis,
interstitial and perivascular fibrosis, and greater incidence of proteinaceous casts as
compared to male RenTgMK mice or female mice. Histological scoring of renal damage by
trained observers blinded to genotype confirmed that RAMP3 loss did not influence renal
damage in female mice, but significantly exacerbated renal disease in male mice (p<0.05,
Figure 2B).
3.4 Loss of RAMP3 exacerbates cardiac hypertrophy in male, but not female, mice with
chronic hypertension
To determine whether RAMP3 might impart sex-dependent cardioprotection on the heart,
we further characterized the hearts of male and female mice that were either wild-type or
homozygous null for RAMP3 and heterozygous for the RenTgMK transgene. Consistent
with our previously published studies [25], there were no significant differences between
RAMP3 null and wildtype animals in any parameter measured, and thus the results of Table
1 are presented as pooled WT data. Table 1 shows that RenTgMK and RenTgMK;Ramp3−/−
mice developed cardiac hypertrophy as judged by an increase in left ventricle/body weight
(LV:BW) ratio compared to age and sex matched controls (p<0.01; Table 1). Interestingly,
and similar to the sex-dependent effects on renal damage (Fig. 2B), loss of RAMP3
significantly increased both LV:BW and RV:BW ratio in male (p<0.05), but not female,
mice on the RenTgMK background.
3.5 Molecular phenotype of cardiac dysfunction resulting from RAMP3 loss
To characterize the molecular phenotype of RenTgMK;Ramp3−/− hearts, we next examined
the expression of several markers indicative of cardiac hypertrophy and heart failure by
quantitative RT-PCR using total RNA extracted from the left ventricle. We included genes
recognized as markers of cardiac hypertrophy (atrial nautriuretic peptide- Nppa/ANP) and of
cardiac metabolism (medium chain acyl dehydrogenase (Acadm/MCAD).
As expected and depicted in Figure 3A, Nppa/ANP expression was significantly associated
with the RenTgMK genotype in both sexes (ANOVA, p<0.01). Post-hoc analysis (Fisher’s
PSLD) revealed that ANP expression was significantly upregulated in the hearts of male, but
not female, RenTgMK;Ramp3−/− mice compared to WT controls (p<0.01). Since
expression of ANP was highly and positively correlated with LV:BW (r2=0.88), it is not
surprising that cardiac tissues of RenTgMK;Ramp3−/− male mice exhibited the greatest
induction of ANP.
Cardiac metabolism is profoundly altered in the failing heart, when cells switch their chief
energy source from fatty acids to carbohydrates. A marker of this transition is the suppressed
expression of MCAD. As depicted in Figure 3B, only male RenTgMK;Ramp3−/− mice
exhibited a significant decrease in MCAD expression compared to WT controls (Fisher’s
PSLD, p<0.05). In addition, MCAD was inversely correlated with LV:BW in male (r2=
−0.84), but not female (r2= −0.007), RenTgMK mice. Taken together, the molecular
Barrick et al. Page 6













phenotype of RenTgMK;Ramp3−/− male mice is consistent with exacerbated cardiac
hypertrophy and suggestive of heart failure.
3.6 Pathological changes in the hearts of RenTgMK;Ramp3−/− mice
Comparison of Masson’s trichrome staining of the hearts of RenTgMK and
RenTgMK;Ramp3−/− mice revealed gender differences in the degree of perivascular (PV)
and interstitial (IS) fibrosis, with male mice more severely affected than female mice
regardless of RAMP3 genotype (Figure 4A). Scoring for severity of fibrosis revealed that
RenTgMK and RenTgMK:Ramp3−/− mice had similar degrees of fibrosis, independent of
sex or genotype (Males: RenTgMK = 2.2 +/− 0.3 (n=6); RenTgMK:Ramp3−/− = 1.5 +/− 0.4
(n=4); Females: RenTgMK = 1.3 +/− 0.3 (n=9); RenTgMK:Ramp3−/− = 1.1 +/− 0.3 (n=4)).
Cardiomyocyte apoptosis leads to the progressive loss of contractile units and has been
implicated in the pathogenesis of heart failure. Several studies in our lab and others have
demonstrated the importance of AM-activated pro-survival signaling pathways in
cardiomyocytes during development and under stress [17, 21–22, 45–46]. Staining for
apoptotic cells in the hearts of 5 month old mice by TUNEL revealed apoptotic cells near
the base of the heart, in the intraventricular septum and posterior LV wall (Figure 4B).
Quantitation demonstrated a statistically significant 3-fold increase in apoptotic nuclei in the
hearts of RenTgMK;Ramp3−/− male, but not female, mice compared to RenTgMK mice
(Figure 4C).
3.7 RAMP3 loss in male mice depresses cardiac function resulting in heart failure
Concentric cardiac hypertrophy without dilatation or overt heart failure was previously
reported in RenTgMK mice, with over half of male RenTgMK dying suddenly between 6–8
months of age accompanied by electrocardiographic abnormalities [37]. To determine if
genetic loss of Ramp3 affected cardiac function in RenTgMK mice, we performed
echocardiography on 5 month-old male and female animals. As shown in Table 2,
RenTgMK mice displayed a phenotype similar to previous reports-- concentric or
compensated hypertrophy, indicated by increased left ventricular wall thickness and
sustained fractional shortening. Female RenTgMK;Ramp3−/− mice had a similar phenotype
of concentric, compensated hypertrophy. However, male RenTgMK;Ramp3−/− mice further
displayed a significant increase in left ventricular end diastolic and systolic dimension,
accompanied with depressed fractional shortening (%FS). Representative B-Mode and M-
mode tracings from male mice are shown in Figure 5A. These functional data demonstrate
that male RenTgMK;Ramp3−/− mice suffer from impaired cardiac contractility.
To determine whether loss of Ramp3 altered the life span of male RenTgMK mice, we aged
RenTgMK;Ramp3−/− male mice beyond six months of age (n=7). We did not observe
decreased survival among these mice compared to RenTgMK mice, indicating that despite
the exacerbation of the RenTgMK phenotype, there did not appear to be any overall
difference in survival rates in male RenTgMK;Ramp3−/− mice compared to male RenTgMK
mice with intact Ramp3.
Further characterization of cardiac function at serial time points on the same animals
revealed that male RenTgMK;Ramp3−/− mice had evidence of concentric cardiac
hypertrophy by 3.5 months of age, and eventually developed progressive LV dilatation and
systolic failure by 5 months of age (Figure 5B and 5C). These data demonstrate that loss of
RAMP3 promoted decompensated hypertrophy and transition to heart failure, which was not
evident in female RenTgMK;Ramp3−/− mice nor in male RenTgMK mice even at 8 months
of age.
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3.8 Loss of Ramp3 causes increased AKT activation in male, but not female, mice with
chronic hypertension
AKT signaling has emerged as a predominant pathway in the regulation of cardiomyocyte
cell survival and apoptosis, and many of the functions of AM signaling have been attributed
to this pathway [17, 20, 22, 46]. Therefore, we evaluated AKT activation in male and female
RenTgMK and RenTgMK;Ramp3−/− mice. Among male mice, AKT activation was
increased in RenTgMK;Ramp3−/− mice compared to RenTgMK mice with intact Ramp3
(Figure 6A, p<0.01), and these data are consistent with the increase in apoptosis that was
observed in male RenTgMK;Ramp3−/− mice. However, in female mice this increase in AKT
activation was not observed (Figure 6B). In fact, RenTgMK;Ramp3−/− female mice had a
small but significant decrease in AKT activation compared to RenTgMK females (Figure
6B, p<0.02).
3.9 Right ventricular hypertrophy in RenTgMK:Ramp3 −/− mice is not secondary to
pulmonary pathology
Few rodent models of hypertension also exhibit significant right ventricular hypertrophy
(RVH), yet our analysis of RenTgMK;Ramp3−/− male mice revealed pronounced RVH
(Table 1). Common causes of RVH include pulmonary congestion resulting from severe LV
systolic failure and pulmonary arterial hypertension (PAH); conditions that increase
pulmonary resistance and RV work. Chronically elevated AngII levels, like those present in
the RenTgMK model, are thought to promote pulmonary hypertension due to
vasoconstrictor effects and pulmonary vasculature remodeling [47]. Numerous studies have
shown that adrenomedullin, a canonical ligand for RAMP3-associated receptors, serves as a
biomarker and therapeutic agent for PAH [48]. In addition, RAMP3 expression is strongly
induced in the lungs under conditions of pulmonary stress such as sepsis and hypoxia [43,
49–50]. Therefore, we wondered whether genetic loss of Ramp3 might worsen pathological
changes in the lungs, leading to the pronounced RVH observed in male
RenTgMK;Ramp3 −/− mice.
Although echocardiographic studies demonstrated that RenTgMK;Ramp3−/− male mice
developed LV failure, we did not see any differences in wet lung weights nor histological
changes characteristic of pulmonary congestion compared to RenTgMK male mice (data not
shown). One of the earliest changes in PAH is the muscularization of the terminal portion of
the pulmonary arterial vascular tree, caused by hyperplasia of vascular smooth muscle cells.
As revealed by Masson’s trichrome staining and immunohistochemical staining for alpha
smooth muscle actin, modest muscularization of terminal arterioles was observed in lungs of
RenTgMK mice, however there was no difference in percent of muscularized arterioles or
arteriolar wall thickness by Ramp3 genotype (Figure 7A and B). Together, these data lead us
to conclude that the increased RVH observed in RenTgMK;Ramp3−/− male mice is not due
to pulmonary congestion, PAH or other pathological changes in the lungs. Therefore, we
conclude that RVH results from a primary effect of RAMP3 loss on cardiomyocytes in the
setting of chronic hypertension.
4. Discussion
Within the RAMP family, RAMP3 has several unique features which argue for a protective
role in cardiovascular disease. In the unstressed heart, RAMP3 is only detected at low levels,
while RAMP2 is highly expressed [51–53]. However, numerous studies including our own,
demonstrate that under conditions of CV stress, inflammation, hypoxia or oxidative stress,
the expression of RAMP2 is markedly down-regulated with a concomitant and robust up-
regulation of RAMP3 gene expression [54]. The interaction of RAMP3, but not RAMP1 or
RAMP2, with molecules involved in GPCR trafficking (NSF and NHERF) has led to the
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hypothesis that this dynamic “RAMP2/3 switch” may function as a protective mechanism by
increasing CLR responsiveness to AM, or similarly, of other GPCRs to their cognate
ligands. Ramp3 is also highly expressed in the kidney and Nowak et al. have shown that it
plays an essential function for mediating the effects of AM on rat mesangial cells [55].
Finally, RAMP3 is one of the most potently estrogen-induced genes in mice and contains
functional estrogen receptor response elements in its promoter. When these unique features
of RAMP3 are considered in the context of our current findings, we conclude that there exist
strong sexually dimorphic cardioprotective roles for RAMP3 during chronic hypertension,
which may be further influenced by several, functionally-significant, genomic RAMP3
variants present in the human population [56].
We have previously used the RenTgMK model to reveal remarkably similar sex-dependent
cardiovascular phenotypes in mice that lack one copy of the AM gene, RenTgMK;AM+/−.
Importantly, these two studies were performed on an identical isogenic genetic background,
SvEv129/6, so that phenotypic comparisons between the cardiovascular responses of AM+/−
and Ramp3−/− mice can be made. For both AM+/− and Ramp3−/− mice, we observed a
worsening of cardiac hypertrophy and kidney damage, with no change in MAP or cardiac
fibrosis, in male mice. Interestingly, female AM+/− and Ramp3−/− mice were protected from
these exacerbated cardiovascular pathologies, likely due to a shared sex-dependent signaling
pathway, which can partially be attributed to increased expression of Calcrl in Ramp3−/−
mice. Therefore, the modest, yet significant up-regulation of Calcrl gene expression in both
male and female Ramp3−/− mice suggests that the function of RAMP3 is likely coordinated
with overall levels of AM signaling.
Specific cardioprotective mechanisms downstream of AM/CLR/RAMP3 activation remain
to be elucidated. Studies by Sexton and colleagues have shown that second messenger
signaling and coupling of G proteins downstream of several GPCRs is influenced by
association with RAMPs, implying that a CLR/RAMP3 complex may elicit a different
intracellular second messenger response than a CLR/RAMP2 complex. It has been well
established that exogenous AM is cardioprotective in acute CV stress (such as ischemia-
reperfusion injury) by activating AKT signaling and limiting apoptosis [17, 20, 22, 46] but it
is not known if CLR/RAMP2 or CLR/RAMP3 complexes mediate this response. We found
increased apoptosis and increased Akt activation in the hearts of male RenTgMK;Ramp3−/−
mice, which were distinctly absent in the hearts of female RenTgMK;Ramp3−/− mice. An
association of high cardiac apoptosis and increased AKT signaling has been demonstrated
by several other groups [57–58]. Our findings are consistent with these studies and further
demonstrate an essential role for RAMP3 in regulating the PI3-kinase/AKT survival
pathway in the heart. Future studies will investigate if the PI3-kinase/AKT survival pathway
is differentially activated by AM/CLR/RAMP3 versus AM/CLR/RAMP2 complexes.
Since the RAMPs have a broader tissue distribution than CLR or its ligands, we and others
hypothesized that additional GPCRs require the RAMPs for cellular trafficking and
signaling [59–60]. Indeed, in the dozen years since RAMPs were discovered, calcitonin
[61], vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide 1, glucagon,
parathyroid hormone 1 and 2 receptors [59], calcium sensing receptor [62] and secretin [63]
have all been shown to partner with the RAMPs. Since RAMP3 can interact with many
other members of family B GPCRs we cannot exclude the possibility that the observed
cardioprotective effects of RAMP3, and their influence by sex, are mediated by other
GPCRs beyond CLR. Because more than 50% of all clinically available drugs target
GPCRs, there is great interest in understanding pharmacological and biochemical properties
of the RAMPs with the ultimate goal of manipulating the GPCR/RAMP interface for
treatment of human disease. Ultimately, small molecule agonists targeting the GPCR/
RAMP3 interface may prove useful for gender-tailored therapies for heart failure.
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We have performed a comprehensive cardiovascular characterization of male and female
Ramp3−/− mice in the context of angiotensin II-mediated hypertension. Consistent with
previous studies identifying Ramp3 as an estrogen-regulated gene, we found that Ramp3
gene expression is induced, particularly in the hearts of female mice, under conditions of
cardiovascular stress. Genetic loss of RAMP3 did not affect the development of
hypertension, however renal damage, cardiac hypertrophy and cardiac apoptosis were
significantly exacerbated in male Ramp3−/− mice carrying the RenTgMK transgene.
Consequently, echocardiography studies revealed that male RenTgMK;Ramp3−/− mice
developed left ventricular dilatation, depressed systolic function, cardiac decompensation
and increased AKT activation compared to female RenTgMK and RenTgMK;Ramp3−/−
mice. Collectively, these data support a sexually dimorphic cardioprotective role of RAMP3
in the setting of chronic hypertension. The elucidation of pharmacologically-tractable GPCR
pathways that are important in controlling the cardiovascular adaptation to chronic
hypertension provides promise for future gender-tailored approaches for the treatment of
heart failure.
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• RAMP3 is an estrogen-regulated GPCR modifier protein induced during CV
disease.
• We bred Ramp3−/− and RenTgMK mice, a genetic model of AngII-mediated
CV disease.
• Male, but not female, Ramp3−/− mice suffer cardiac hypertrophy and renal
damage.
• Male Ramp3−/− mice develop LV dilatation and decompensated heart failure.
• We elucidate a pharmacologically-tractable pathway in sex-dependent CV
adaptation.
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Quantitative PCR was used to compare the expression of A) Ramp1, B) Ramp2 and C)
Calcrl in hearts of Ramp3−/− mice. D) Ramp3 in CV tissues of WT and RenTgMK mice.
The number of animals per genotype is depicted in the bars of the graphs. *p<0.05,
**p<0.01
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Ramp3−/− male, but not female, mice suffer greater degree of renal damage in response to
RenTgMK than wildtype mice. A) Representative Masson’s trichrome stained sections
showing kidney damage (proteinacous casts-black arrows; interstitial fibrosis-asteriks and
perivascular fibrosis-open arrow) that is more severe in male RenTgMK;RAMP3−/− mice.
B) Renal damage was scored using arbitrary units for the severity of glomerular sclerosis,
vascular fibrosis, interstitial fibrosis and proteinaceous casts.
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Quantitative PCR was used to compare the expression of markers of hypertrophy and heart
failure in the LVs of WT, RenTgMK and RenTgMK;Ramp3−/− mice. The number of
animals per genotype is depicted in the bars in each graph. (A) Nppa/ANP, ANP=atrial
nautriuretic peptide. (B) Acadm/MCAD, MCAD= medium chain acyl dehydrogenase.
*p<0.05 vs WT.
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Pathological changes in the hearts of RenTgMK;Ramp3−/− mice. A) Representative
Masson’s trichrome stained histological sections of the heart s of RenTgMK and
RenTgMk;Ramp3−/− mice. B) Representative sections showing TUNEL-positive cardiac
cells depicted by white arrows. C) Quantification of the number of TUNEL-positive cardiac
cells from the hearts of RenTgMK and RenTgMK;Ramp3−/− male and female mice,
revealing a statistically significant increase in male RenTgMK;Ramp3−/− mice.
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A) Representative B mode images and corresponding M-mode tracings from RenTgMK and
RenTgMK;Ramp3−/− male mice. B) Serial echocardiography studies were performed in
RenTgMK and RenTgMK;Ramp3−/− male mice. Measured parameters are plotted over time
in months. LVED,d=left ventricle end dimension, diastole; LVED,s=left ventricle end
dimension, systole; LVPWTh,d=left ventricle posterior wall thickness, diastole;
%FS=percent fractional shortening. *p<0.05 vs RenTgMK;Ramp3−/−.
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Western blotting for AKT activation state in heart lysates from RenTgMK and
RenTgMK;Ramp3−/− mice. A) Representative AKT western blots and quantitation of male
RenTgMK and RenTgMK;Ramp3−/− heart lysates. Samples were run on the same blot but
middle lanes were removed from the image. **p<0.01 B) Representative AKT western blots
and quantitation of female RenTgMK and RenTgMK;Ramp3−/− heart lysates. *p<0.02
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Small pulmonary arteries (<100 um) of male RenTgMK and RenTgMK;Ramp3−/− mice are
muscularized. A) Representative sections of the lungs of WT, RenTgMK and
RenTgMK;Ramp3−/− male mice stained with Masson’s Trichrome or with FITC-conjugated
anti-alpha smooth muscle actin (αSMA). Scale bars:100 μM B) Percentage of muscularized
small pulmonary arterioles in WT (n=135), RenTgMK (n=57), and RenTgMK;Ramp3−/−
mice (n=66) (ANOVA, p<0.005). C) Total arteriole area, lumen area and wall thickness was
measured in WT (n=102), RenTgMK (n=286) and RenTgMk;Ramp3−/− (n=210) arterioles.
Results are summarized as the ratio of arteriolar wall thickness to total vessel area (ANOVA,
p<0.001).
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